$DRI

Weekly Recap: Darden Restaurants, Inc. Q1 FY2027 call and KeyBanc $237 PT

Darden Restaurants (DRI) will report Q1 FY2027 results on Sept. 24, 2026, with an earnings call at 8:30 a.m. ET. KeyBanc maintained an Overweight rating and raised its price target to $237.00 from $228.00.

Original reporting
Published Aug 31, 2026, 11:22 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Weekly Recap: Darden Restaurants, Inc. Q1 FY2027 call and KeyBanc $237 PT — source image
Decision brief

The 30-second read

$DRIBullishMed
01

Why it matters

The target increase signals analyst confidence, likely prompting short‑term buying interest before the earnings call.

02

Market read

Analyst upgrade and upcoming earnings call create a near‑term trading catalyst for DRI.

03

What to watch

Potential supply‑chain cost pressures could temper upside despite the higher target.

Relevance 7/10Novelty 7/10Timing: pre‑market on Sept 24, 2026

Background

KeyBanc maintains an Overweight rating on Darden Restaurants and lifts its price target from $228 to $237 ahead of the Q1 FY2027 earnings release.

Company-level read

Ticker impact

$DRIBullishMedium confidence
Context

KeyBanc raised its price target for Darden Restaurants to $237 and announced the upcoming fiscal 2027 Q1 earnings call on Sept 24, 2026.

Expected impact

Potential modest price appreciation ahead of the earnings release.

Evidence & confidence

Target raise reflects improved outlook; no new financials yet, but market may price in expectations.

Market effects

Restaurant sector may see heightened attention ahead of earnings season.

U.S. consumer discretionary sentiment could be nudged by DRI's guidance expectations.

Limited to U.S. markets; no direct global ripple.

Counterpoint

Investors may wait for actual earnings results before acting on the target raise.

Key entities

  • Darden Restaurants, Inc.

    U.S. restaurant operator (NYSE:DRI).

  • KeyBanc Capital Markets

    Investment bank providing the rating and price target.

Related articles

$CMGMed

Baird Reshuffles Restaurant Ratings: Starbucks, Cava Top Picks as Chipotle, Domino's Cut to Neutral — BigGo Finance

Baird downgraded Chipotle (CMG) to Neutral, cutting its price target to $40, citing slower growth and higher reinvestment needs. Domino's (DPZ) and Black Rock Coffee Bar (BRCB) were also downgraded. Darden (DRI) was upgraded to Outperform with a $250 target. Baird favors Cava (CAVA), Starbucks (SBUX), and others with strong unit economics and growth potential.

$CMGMed

Baird downgrades Chipotle, Domino’s as restaurant divergence widens

Baird downgraded Chipotle (CMG), Domino's (DPZ), and Black Rock Coffee Bar (BRCB) to Neutral, citing slower growth and competitive pressures. It upgraded Darden (DRI) to Outperform, praising its strong fundamentals. Price targets were adjusted for each. Baird also initiated coverage of Brinker (EAT) and Jersey Mike's with Outperform ratings, and named Cava (CAVA), Brinker, Starbucks (SBUX), and Dutch Bros (BROS) as top picks.

$DRIHighAI 8/10

Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Darden Restaurants (DRI) reached a 52-week high in 2026, with fiscal sales surpassing $13 billion. Key brands like Olive Garden and LongHorn Steakhouse drove growth, with Q4 revenue up 13.7% YoY. Darden's stock rose 18% this year, supported by strong earnings and a new $1.5 billion share repurchase plan. The company provided optimistic 2027 guidance, including sales between $13.6B and $13.75B. Competitors like Domino's (DPZ) and Chipotle (CMG) faced weaker sales and stock declines.

$DRIMed

DRI Healthcare Announces Receipt of Put Price on EKTERLY

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) said it received about US$178 million as the put price after exercising a contractual put option tied to its royalty participation right in EKTERLY. The put was exercised after Chiesi Group completed its acquisition of KalVista Pharmaceuticals. The transaction is now complete and the royalty right has terminated.

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.